Wet Age-Related Macular Degeneration
Pegcetacoplan for geographic atrophy receives negative opinion from European committee
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on a marketing authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release.
VIDEO: Duker shares EyePoint pipeline progress
WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD.
VIDEO: Faricimab demonstrates reduction in pigment epithelial detachment
In this video, Esther M. Bowie, MD, discusses a post hoc analysis comparing faricimab and aflibercept for the reduction of pigment epithelial detachment in patients with wet age-related macular degeneration.
Medsan to provide testing for RetinalGeniX study on personalizing wet AMD care
RetinalGeniX has contracted with Medsan to provide diagnostic testing for a study on personalizing medical evaluations for patients with wet age-related macular degeneration.
VIDEO: Novel VEGF inhibitor under development for wet AMD
ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Angelo Maria Minnella, MD, speaks about sozinibercept, a VEGF-C/D inhibitor under development for the treatment of wet age-related macular degeneration.
Phase 2 trial of EYP-1901 in wet AMD meets all endpoints
The phase 2 DAVIO 2 trial of EYP-1901 met all primary and secondary endpoints in patients with wet age-related macular degeneration, EyePoint Pharmaceuticals announced in a press release.
VIDEO: AVD-104 shows stability, GA lesion size reduction in phase 2/3 trial
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Mohamed Genead, MD, CEO of Aviceda Therapeutics, discusses a trial investigating AVD-104 for geographic atrophy secondary to age-related macular degeneration.
OnPoint receives investigational device exemption for pseudophakic capsular lens magnifier
OnPoint Vision has announced FDA investigational device exemption approval for its AccuraSee device, according to a press release.
Be mindful of anti-VEGF injection speed, volume in patients with severe glaucoma
SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, diabetic macular edema or retinal vein occlusion who have severe glaucoma, be mindful of the speed and volume of injections.
Develop practice implementation strategy for integration of new retinal therapies
SAN FRANCISCO — It is important for ophthalmologists to understand FDA indications and develop a proper practice implementation strategy for new retinal drugs entering the market, according to a speaker here.